Annovis Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
Annovis Bio, Inc. (ANVS), an emerging growth company, filed this Current Report on October 26, 2025. The filing details a material definitive agreement entered into on the same date regarding a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered Direct Offering and Director Subscription.
- Shares Issued: 1,670,732 shares of Common Stock in total.
- 597,561 shares sold to purchasers under a Securities Purchase Agreement.
- 1,073,171 shares subscribed by two Board members.
- Offering Price: $2.05 per share.
- Gross Proceeds: Approximately $3.425 million (before expenses).
- Placement Agent Fee: 7.0% cash fee on gross proceeds (excluding shares sold to directors/officers) plus reimbursement of expenses.
- Placement Agent Warrants: Warrants to purchase 83,537 shares (5.0% of total offering) at an exercise price of $2.5625 per share, exercisable immediately with a 5-year term.
Material Changes and Use of Proceeds
The filing does not report changes to historical revenue, profit, or cash flow metrics as this is a transactional filing rather than a periodic financial report. The primary material change is the increase in share count and capitalization.
Use of Proceeds: Net proceeds are designated for:
- Continued clinical development of the lead compound Buntanetap in a Phase 3 study for Alzheimer's disease.
- Working capital and general corporate purposes.
Guidance, Outlook, and Restrictions
Lock-Up and Issuance Restrictions:
- Until November 28, 2025: The Company and its directors/officers cannot issue securities without Purchaser consent.
- Until October 14, 2026: The Company is restricted from issuing or announcing the issuance of Common Stock or related securities involving a Variable Rate Transaction, subject to exceptions.
Closing Date: Expected on or about October 28, 2025, subject to customary conditions.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting offering expenses.
- Confirm the dilution impact of the 1,670,732 new shares and 83,537 placement agent warrants on existing shareholders.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination provisions and indemnification obligations.
- Monitor the progress of the Phase 3 clinical trial for Buntanetap as the primary use of funds.